Emulex Shareholder Alert – National Securities Law Firm Seeks Higher Price For Shareholders In Connection With Acquisition. Encourages Shareholders To Contact Law Firm For More Information

February 26, 2015
New York, New York

Tripp Levy PLLC, a leading national securities and shareholder rights law firm, announces that it is investigating the acquisition of Emulex Corporation (NYSE: “ELX”) (“Emulex” or the “Company”) on behalf of its’ shareholders. Avago Technologies Limited and Emulex have entered into an agreement under which Avago will acquire Emulex for $8 per share in cash.

Our investigation has determined that the offer price of only $8 per share unfairly under-values the true going forward inherent value of the Company and that shareholders are not receiving the maximum value for their shares. Indeed, among other things, only a few years ago, Broadcom Corp. offered to acquire Emulex for $11 per share, and the transaction is expected to be immediately accretive to Avago’s non-GAAP earnings per share. The investigation further seeks to determine whether senior management of Emulex are acting in their own self-interests at the expense of shareholders. In fact, senior members of Emulex management have agreed to tender their shares in support of the transaction.

If you are a shareholder of Emulex and would like additional information as to how the acquisition may affect your rights as a shareholder, and how you may be eligible to obtain a higher price for your shares, please contact us toll free at 1-800-906-6432 or contact us via our website.

Tripp Levy PLLC represents individual and institutional shareholders in mergers and acquisitions transactions and, along with its affiliate, has recovered billions of dollars for shareholders in securities actions around the globe. Tripp Levy PLLC is affiliated with the law firm Milberg LLP. The National Law Journal has named Milberg one of the “50 Elite Trial Lawyer Firms” and one of the “50 Leading Plaintiff Firms in America.” Attorney advertising. Prior results do not indicate a similar outcome.